Biomerica's InFoods Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment - Seite 3

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements, written statements and other press release issued, made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the timing of the completion of clinical studies and clinical trials, the final clinical results from clinical trials, potential partnering opportunities, the efficacy of the Company's COVID-19 test and other tests and products developed by the Company, FDA clearance, EUA clearance, receipt of CE Mark, the rapidity of testing results, uniqueness of a product, pricing of the Company's various test kits, demand for domestic and international orders for the Company's COVID-19 tests and other Company products, availability of the Company's COVID-19 tests, and patent protection on the Company's products and technologies. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company's COVID-19 tests, InFoods tests and other Company products; regulatory approvals necessary prior to commercialization of the Company's COVID-19 tests and other Company products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; competition from products similar to those developed or sold by the Company and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that could make it difficult or impossible for the Company to maintain current operations; regulations and the Company's ability to obtain patent protection on any aspects of its tests and technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company competes, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.